Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

Pfizer's head of digital devices says the industry is close to a 'revolution' in using measures from wearables in clinical ...

Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no ...

On behalf of the Pfizer team, thank you for joining us ... We had a Phase II readout of ponsegromab, which is another in-house discovered and developed by us. We are encouraged by the potential ...

Tim Opler, a managing director at Stifel, has even suggested that ponsegromab could become a “monster” drug, with potential ...

Pfizer Inc. (NYSE:PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary ...

Ponsegromab is under clinical development by Pfizer and currently in Phase II for Congestive Heart Failure (Heart Failure). According to... Likelihood of Approval and Phase Transition Success Rate ...

Pfizer's diverse operations put it in an excellent position to grow in the long run. It doesn't have a top weight loss treatment on the market, but that could change. Its above-average dividend ...

Pharmaceutical giant Pfizer has agreed to pay $35 million to settle allegations that it unlawfully hindered the sale of Lipitor, a drug prescribed to lower cholesterol, resulting in buyers paying ...

Mikael Dolsten; Chief Scientific Officer & President, Pfizer Research and Development; Pfizer Inc Andrew Baum; Chief Strategy and Innovation Officer & Executive Vice President; Pfizer Inc Louise ...